Company intelligence / Profile preview

OncoPep

North Andover, Massachusetts, United States

Ownership: Private
Development stage: Phase 1

Overview

OncoPep is developing peptide-based therapeutic cancer vaccines and immunotherapies. Its lead candidate, PVX‑410, has reached Phase 2 clinical trials for metastatic triple-negative breast carcinoma. Other programs target multiple myeloma and solid tumors. Early clinical data suggest that combining peptide vaccines with immune checkpoint inhibitors can produce durable responses in advanced cancers.

Therapeutic areas: Oncology
Modalities: PeptidesTherapeutic vaccineSmall molecule drug
Industry: Biotech

Drug pipeline

1 asset

pvx-410

Beyond the preview

Go deeper on OncoPep.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoPep.

Explore the full profile